EXPEDITED REVIEW
A Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial Fibrillation
The APAF (Ablation for Paroxysmal Atrial Fibrillation) Study
Carlo Pappone, MD, PhD, FACC*,*,
Giuseppe Augello, MD*,
Simone Sala, MD*,
Filippo Gugliotta, BEng*,
Gabriele Vicedomini, MD*,
Simone Gulletta, MD*,
Gabriele Paglino, MD*,
Patrizio Mazzone, MD*,
Nicoleta Sora, MD*,
Isabelle Greiss, MD*,
Andreina Santagostino, MD*,
Laura LiVolsi, MD*,
Nicola Pappone, MD ,
Andrea Radinovic, MD*,
Francesco Manguso, MD, PhD* and
Vincenzo Santinelli, MD*,
* Division of Cardiac Pacing and Electrophysiology, San Raffaele University Hospital, Milan, Italy
Salvatore Maugeri Foundation, IRCCS, Telese Terme, Italy
Manuscript received August 2, 2006;
revised manuscript received August 23, 2006,
accepted August 28, 2006.
* Reprint requests and correspondence: Dr. Carlo Pappone, Department of Arrhythmology, San Raffaele University Hospital, Via Olgettina 60, 20132—Milan, Italy. (Email: carlo.pappone{at}hsr.it). or (Email: vincenzo.santinelli{at}hsr.it).
OBJECTIVES: We compared ablation strategy with antiarrhythmic drug therapy (ADT) in patients with paroxysmal atrial fibrillation (PAF).
BACKGROUND: Atrial fibrillation (AF) ablation strategy is superior to ADT in patients with an initial history of PAF, but its role in patients with a long history of AF as compared with ADT remains a challenge.
METHODS: One hundred ninety-eight patients (age, 56 ± 10 years) with PAF of 6 ± 5 years' duration (mean AF episodes 3.4/month) who had failed ADT were randomized to AF ablation by circumferential pulmonary vein ablation (CPVA) or to the maximum tolerable doses of another ADT, which included flecainide, sotalol, and amiodarone. Crossover to CPVA was allowed after 3 months of ADT.
RESULTS: By Kaplan-Meier analysis, 86% of patients in the CPVA group and 22% of those in the ADT group who did not require a second ADT were free from recurrent atrial tachyarrhythmias (AT) (p < 0.001); a repeat ablation was performed in 9% of patients in the CPVA group for recurrent AF (6%) or atrial tachycardia (3%). At 1 year, 93% and 35% of the CPVA and ADT groups, respectively, were AT-free. Ejection fraction, hypertension, and age independently predicted AF recurrences in the ADT group. Circumferential pulmonary vein ablation was associated with fewer cardiovascular hospitalizations (p < 0.01). One transient ischemic attack and 1 pericardial effusion occurred in the CPVA group; side effects of ADT were observed in 23 patients.
CONCLUSIONS: Circumferential pulmonary vein ablation is more successful than ADT for prevention of PAF with few complications. Atrial fibrillation ablation warrants consideration in selected patients in whom ADT had already failed and maintenance of sinus rhythm is desired. (A Controlled Randomized Trial of CPVA Versus Antiarrhythmic Drug Therapy in for Paroxysmal AF: APAF/01; http://clinicaltrials.gov/ct/show; NCT00340314
[ClinicalTrials.gov]
)
|
Abbreviations and Acronyms
| | AAD = antiarrhythmic drug | | ADT = antiarrhythmic drug therapy | | AF = atrial fibrillation | | AT = atrial tachyarrhythmia | | CPVA = circumferential pulmonary vein ablation | | EF = ejection fraction | | PAF = paroxysmal atrial fibrillation | | SR = sinus rhythm |
|
This article has been cited by other articles:
|
|
|
|
 
R. Beukema, W. P. Beukema, H. T. Sie, A. R. Misier, P. P. Delnoy, and A. Elvan
Monitoring of atrial fibrillation burden after surgical ablation: relevancy of end-point criteria after radiofrequency ablation treatment of patients with lone atrial fibrillation
Interactive CardioVascular and Thoracic Surgery,
December 1, 2009;
9(6):
956 - 959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Arya, G. Hindricks, P. Sommer, Y. Huo, A. Bollmann, T. Gaspar, K. Bode, D. Husser, H. Kottkamp, and C. Piorkowski
Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients
Europace,
November 3, 2009;
(2009)
eup331v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Burkhardt and A. Natale
New Technologies in Atrial Fibrillation Ablation
Circulation,
October 13, 2009;
120(15):
1533 - 1541.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Anter and D. J. Callans
Pharmacological and Electrical Conversion of Atrial Fibrillation to Sinus Rhythm Is Worth the Effort
Circulation,
October 6, 2009;
120(14):
1436 - 1443.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Y. See, K. C. Roberts-Thomson, W. G. Stevenson, P. C. Camp, and B. A. Koplan
Atrial Arrhythmias After Lung Transplantation: Epidemiology, Mechanisms at Electrophysiology Study, and Outcomes
Circ Arrhythm Electrophysiol,
October 1, 2009;
2(5):
504 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Lindsay
Should catheter ablation be the first line of treatment for atrial fibrillation?
Cleveland Clinic Journal of Medicine,
September 1, 2009;
76(9):
503 - 506.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. CHOWDHURY, W. R. LEWIS, R. A. SCHWEIKERT, and J. E. CUMMINGS
Ablation of atrial fibrillation: What can we tell our patients?
Cleveland Clinic Journal of Medicine,
September 1, 2009;
76(9):
543 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Terasawa, E. M. Balk, M. Chung, A. C. Garlitski, A. A. Alsheikh-Ali, J. Lau, and S. Ip
Systematic Review: Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation
Ann Intern Med,
August 4, 2009;
151(3):
191 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Reynolds, P. Zimetbaum, M. E. Josephson, E. Ellis, T. Danilov, and D. J. Cohen
Cost-Effectiveness of Radiofrequency Catheter Ablation Compared With Antiarrhythmic Drug Therapy for Paroxysmal Atrial Fibrillation
Circ Arrhythm Electrophysiol,
August 1, 2009;
2(4):
362 - 369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Jons, P. S. Hansen, A. Johannessen, G. Hindricks, P. Raatikainen, O. Kongstad, H. Walfridsson, S. Pehrson, H. Almroth, J. Hartikainen, et al.
The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) Trial: clinical rationale, study design, and implementation
Europace,
July 1, 2009;
11(7):
917 - 923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Crandall, D. J. Bradley, D. L. Packer, and S. J. Asirvatham
Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Mayo Clin. Proc.,
July 1, 2009;
84(7):
643 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Pontoppidan, J C Nielsen, S H Poulsen, H K Jensen, H Walfridsson, A K Pedersen, and P S Hansen
Prophylactic cavotricuspid isthmus block during atrial fibrillation ablation in patients without atrial flutter: a randomised controlled trial
Heart,
June 15, 2009;
95(12):
994 - 999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. B. Forleo and C. Tondo
Atrial fibrillation: cure or treat?
Therapeutic Advances in Cardiovascular Disease,
June 1, 2009;
3(3):
187 - 196.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Belhassen
A 1 per 1,000 mortality rate after catheter ablation of atrial fibrillation an acceptable risk?
J. Am. Coll. Cardiol.,
May 12, 2009;
53(19):
1804 - 1806.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Andrikopoulos, S. Tzeis, N. Maniadakis, H. E. Mavrakis, and P. E. Vardas
Cost-effectiveness of atrial fibrillation catheter ablation
Europace,
February 1, 2009;
11(2):
147 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Callans
Apples and Oranges: Comparing Antiarrhythmic Drugs and Catheter Ablation for Treatment of Atrial Fibrillation
Circulation,
December 9, 2008;
118(24):
2488 - 2490.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Jais, B. Cauchemez, L. Macle, E. Daoud, P. Khairy, R. Subbiah, M. Hocini, F. Extramiana, F. Sacher, P. Bordachar, et al.
Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study
Circulation,
December 9, 2008;
118(24):
2498 - 2505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Malmborg, S. Lonnerholm, and C. Blomstrom-Lundqvist
Acute and clinical effects of cryoballoon pulmonary vein isolation in patients with symptomatic paroxysmal and persistent atrial fibrillation
Europace,
November 1, 2008;
10(11):
1277 - 1280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm and J. A. Reiffel
Defining endpoints in clinical trials on atrial fibrillation
Eur. Heart J. Suppl.,
September 1, 2008;
10(suppl_H):
H55 - H78.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Aliot and J. N. Ruskin
Controversies in ablation of atrial fibrillation
Eur. Heart J. Suppl.,
September 1, 2008;
10(suppl_H):
H32 - H54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Katritsis
Catheter Ablation of Atrial Fibrillation: For Whom and How?
Angiology,
August 1, 2008;
59(2_suppl):
103S - 106S.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A Lubitz, A. Fischer, and V. Fuster
Catheter ablation for atrial fibrillation
BMJ,
April 12, 2008;
336(7648):
819 - 826.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Katritsis, M. A. Wood, E. Giazitzoglou, R. K. Shepard, G. Kourlaba, and K. A. Ellenbogen
Long-term follow-up after radiofrequency catheter ablation for atrial fibrillation
Europace,
April 1, 2008;
10(4):
419 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Noheria, A. Kumar, J. V. Wylie Jr, and M. E. Josephson
Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation: A Systematic Review
Arch Intern Med,
March 24, 2008;
168(6):
581 - 586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Moreira, C. Timmermans, H. J.J. Wellens, Y. Mizusawa, S. Philippens, D. Perez, and L.-M. Rodriguez
Can Common-Type Atrial Flutter Be a Sign of an Arrhythmogenic Substrate in Paroxysmal Atrial Fibrillation?: Clinical and Ablative Consequences in Patients With Coexistent Paroxysmal Atrial Fibrillation/Atrial Flutter
Circulation,
December 11, 2007;
116(24):
2786 - 2792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pappone and V. Santinelli
Non-fluoroscopic mapping as a guide for atrial ablation: current status and expectations for the future
Eur. Heart J. Suppl.,
December 1, 2007;
9(suppl_I):
I36 - I47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)
Eur. Heart J.,
November 2, 2007;
28(22):
2803 - 2817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association
Europace,
November 1, 2007;
9(11):
1006 - 1023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. O'Neill, P. Jais, M. Hocini, F. Sacher, G. J. Klein, J. Clementy, and M. Haissaguerre
Catheter Ablation for Atrial Fibrillation
Circulation,
September 25, 2007;
116(13):
1515 - 1523.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Jais and D. L. Packer
Ablation vs. drug use for atrial fibrillation
Eur. Heart J. Suppl.,
September 1, 2007;
9(suppl_G):
G26 - G34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Frye
Update in Cardiology
Ann Intern Med,
August 7, 2007;
147(3):
180 - 186.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Calkins, J. Brugada, D. L. Packer, R. Cappato, S.-A. Chen, H. J.G. Crijns, R. J. Damiano Jr, D. W. Davies, D. E. Haines, M. Haissaguerre, et al.
HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and Approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society.
Europace,
June 1, 2007;
9(6):
335 - 379.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Pulmonary-Vein Ablation vs. Antiarrhythmic Drugs for Paroxysmal AFib
Journal Watch Cardiology,
January 3, 2007;
2007(103):
5 - 5.
[Full Text]
|
|
|
|
